• ipharmaservices

2019: Annual revenues of top pharmaceutical companies

Updated: Sep 28


Revenues of top pharmaceutical companies in 2019



TOP 10 PHARMACEUTICAL COMPANIES BY REVENUES:

  1. JOHNSON AND JOHNSON: $82.1 billion

  2. ROCHE: $63.3 billion

  3. PFIZER: $51.75 billion

  4. NOVARTIS: $47.45 billion

  5. MERCK: $46.84 billion

  6. GSK: $ 43.92 billion

  7. SANOFI: $39.28 billion

  8. ABBVIE: $33.27 billion

  9. ABBOTT: $31.90 billion

  10. TAKEDA: 31.17 billion

Other major pharma companies are:

  • BMS: $26.15 billion

  • AMGEN: $21.30 billion

  • NOVO NORDISK: $18.30 billion


Also read: Top 15 pharmaceutical companies by revenues in 2020




Janssen reported the annual revenues of $82.1 billion, pharmaceutical segment contributed to $ 42.20 billions


The group has reported growth of 0.6%. The pharmaceutical division reported growth of 3.6%. The growth has been driven by Stelara (ustekinumab), Darzalex (daratumumab), Imbruvica (ibrutinib), Tremfya (guselkumab), Invega Sustenna/Xeplion/Invega Trinza/Trevicta (paliperidone palmitate) . The sales of Remicade declined because of biosimilars.


Roche presented impressive financial data, group sales rose by 9%, reported net sales of USD 63.3 bn

  • Roche sales were increased by 9%. The group has reported USD 63.30 bn

  • The revenues of the pharmaceutical division was CHF 48.5 bn (50.03 bn)

  • The company reported an increase in sales by 13% in the USA, Japan by 9% and international sales by 15%

  • Avastin sales were increased by 4%

  • Rituxan/Mabthera sales in Europe and Japan were affected by biosimilar competition. In Europe, sales were decreased by 33% and 44% in Japan

  • Ocrevus sales were increased by 57%; the company reported sales of CHF 3.7 bn (USD 3.82 bn)




Also read: The United States Healthcare System


Pfizer has reported a decline in sales by 4%; reported annual sales of USD 51.75 bn

  • The revenues were dropped by 4%

  • Eliquis sales were increased by 23%; the company has reported sales of USD 4.22 bn

  • Ibrance sales were increased by 20%. The company has reported revenues of USD 4.96 bn

  • A mere 1 % boosted Prevnar 13 sales, sales of USD 5.85 bn was reported

  • Lyrica revenues were USD 3.32 bn and of Lipitor were USD 1.97 bn

  • Xeljanz reported sales of 2.24 bn and Pfizer share of Enbrel was 1.70 bn


Novartis presented strong financial data supported by Cosentyx and Entresto; sales increased by 9%; reported net sales USD 47.45 bn

  • Novartis announced that full-year net sales rose by 9%. The company has reported net sales of USD 47.45 bn

  • The results were mostly driven by sales of Cosentyx (USD 3.6 bn, increased by 28%), Entresto (USD 1.7 bn, increased by 71%) and Zolgensma

  • The company has reported sales of USD 37.7 from innovative medicines. Sandoz has reported sales of USD 9.7 bn

  • The company’s last year best selling product Gilenya sales were reduced by 4%. The net sales of Gilenya were USD 3.22 bn. The company reported that the sales decreased because of the competition

  • Xolair sales were increased by 13%. The company reported sales of USD 1.17 bn





Merck reported sales of $46.8 billion, an increase of 11%, Keytruda sales were increased by 55%


Merck has reported increase in sales by 11%. The sales were primarily driven by Keytruda.

  • The company reported the sales of Keytruda as more than $ 11 billion, compared to $ 7 billion in 2018

  • Gardasil/ Gardasil 9 revenues were $ 3.74 billion

  • ProQuad / M-M-R II / Varivax were reported as $ 2.23 billion





Our startup needs your support. Please donate to support iPharmaCenter. Click on donate in the header to support us.

Thank you!

For pipeline, market overview, SLRs, and market access reports (syndicate and customised) please write to sales@firstviewinsight.com


For all syndicate reports: Click here

Please donate to support iPharmaCenter. Click on donate button in header to support us. Thank you

©2020 by ipharmaservices